Lacipil (Lacidipine)

Lacidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells. By preventing calcium entry, it causes arterial vasodilation, which decreases peripheral resistance and leads to a reduction in systemic blood pressure.

The exact dosage of Lacipil is determined by the prescribing clinician based on the patient’s blood pressure, age, renal and hepatic function, and concomitant medications. Physicians typically start with a low dose and titrate as needed to achieve target blood pressure.

Safety data for lacidipine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Lacipil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacipil (lacidipine) belongs to the dihydropyridine calcium‑channel blocker class, offering potent arterial vasodilation. Compared with agents such as amlodipine, lacidipine has a longer half‑life and may cause less reflex tachycardia, but individual response and side‑effect profiles vary, so therapy should be individualized.

Lacipil tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight, and excessive heat to maintain potency throughout the shelf life.

Lacipil is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and avoid crushing or chewing the tablet.

Serious adverse events, though rare, include severe hypotension, angioedema, hepatic dysfunction, myocardial infarction, and life‑threatening allergic reactions. Patients should seek immediate medical attention if they experience symptoms such as sudden dizziness, swelling of the face or throat, chest pain, or jaundice.

Lacipil is contraindicated in patients with known hypersensitivity to lacidipine or any excipients, those with severe aortic stenosis, and individuals with uncontrolled heart failure. Caution is also advised for patients with significant liver or kidney impairment, and it should be avoided during pregnancy unless absolutely necessary.